Mauna Kea Technologies SA
PAR:ALMKT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mauna Kea Technologies SA
Cash Taxes Paid
Mauna Kea Technologies SA
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mauna Kea Technologies SA
PAR:ALMKT
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cash Taxes Paid
€366k
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
12%
|
|
|
Biomerieux SA
PAR:BIM
|
Cash Taxes Paid
€151.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
|
Diagnostic Medical Systems SA
PAR:ALDMS
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mauna Kea Technologies SA
Glance View
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France and currently employs 56 full-time employees. The company went IPO on 2011-07-05. The firm specializes in designing, developing, and selling optical biopsy devices and tools. Its products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. The company provides Cellvizio product that is used by medical specialties and is revolutionizing the way physicians diagnose and treat patients making a transformative change in medicine. Its real-time in vivo cellular imaging platform, that delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time.
